Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase) Pipeline Landscape and Therapeutic Assessment in H1 2017

Published on : Jul 03, 2017

Albany, New York, July 03, 2017: According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC - Pipeline Review, H1 2017” has been recently broadcasted to the wide database of Market Research Hub (MRH). This report on the Aminopeptidase N market has been compiled by conducting both primary and secondary research and analyzes the market on the basis of its pipeline review.

The study starts by presenting the comprehensive overview on Aminopeptidase N. his section highlights the development of therapeutics, pipeline products utilized in Aminopeptidase N, and a comparative analysis of these pipeline products. Aminopeptidase N (AP-N) or membrane alanyl aminopeptidase or alanyl aminopeptidase (AAP) is an enzyme encoded by the ANPEP gene. Aminopeptidase N or CD13 is a transmembrane protease present in a wide variety of human tissues and cell types including endothelial, epithelial, leukocyte and fibroblast. It is a multifunctional enzyme, related with tumorigenesis, immune system, pain etc. It has also analyzed that it plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. It also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides and chemokines.

In the next part of the report, the therapeutics still under development by both universities and companies have been presented. Moving further, the clinical late stage and early stage products have been analyzed in this study. The drug profiles, their mechanism of action, and their research and development progress have also been encapsulated in this study.

Moving further, the key dynamics impacting the development of the Aminopeptidase N targeted therapeutics development market has also been compiled in this study. At present, Aminopeptidase N has been associated with the growth of different human cancers and suggested as a suitable target for anti-cancerous therapy. Different approaches have been used to develop new drugs directed to this target, including enzyme inhibitors as well as APN-targeted carrier constructs. Also, it has a role in angiogenesis and promotes cholesterol crystallization.

Click here to get more info with TOC in a PDF Format :

Furthermore, the study also reviews key players involved in Aminopeptidase N targeted therapeutics development with their respective active and dormant projects. The vendor landscape section of the report throws light on the companies excelling in pipeline products in the market for Aminopeptidase N. Currently, MolMed SpA, Nippon Kayaku Co. Ltd. and Pharmaleads SA are the leading companies.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top